HOME >> BIOLOGY >> NEWS
Chromosome losses mean poor survival in childhood leukemia

COLUMBUS, Ohio A new international study of children with a severe form of acute lymphoblastic leukemia (ALL) shows that certain chromosome losses can signal an especially poor response to therapy, but that other chromosome abnormalities have no effect on treatment survial.

The finding should enable doctors to identify patients with severe ALL for additional or experimental therapies when such therapies become available. The study was published in the April issue of the journal Leukemia.

"Overall, we found that many chromosome abnormalities in our group of patients made no difference at all, although particular abnormalities could," says Dr. Nyla A. Heerema, a researcher with The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and first author on the study.

"The results surprised us," she says. "We expected that additional chromosome abnormalities would mean a worse outcome."

The retrospective study involved 249 children diagnosed with ALL between 1986 and 1996 by 10 medical centers in the United States and five other countries. The children had received intensive chemotherapy and their disease had gone into complete remission.

All the children had cancers showing the Philadelphia chromosome, an alteration in the genes that indicates a poorer response to treatment. Sixty-one percent of the patients (153), showed secondary chromosome abnormalities; that is, abnormalities present in addition to the Philadelphia chromosome.

Heerema and her colleagues wanted to learn if secondary chromosome abnormalities contributed to a poor prognosis in children with ALL. They found that having most secondary chromosome abnormalities had little affect on a child's prognosis. It did, however, when they involved the loss of chromosome 7, or the part of it known as 7p, or the loss of a part of chromosome 9 known as 9p.

Among children with cancer c
'"/>

Contact: Darrell E. Ward
Ward-15@medctr.osu.edu
614-293-3737
Ohio State University
4-May-2004


Page: 1 2

Related biology news :

1. Chromosome caps predict bone marrow disease
2. Gene-rich human Chromosome 19 sequence completed
3. Chromosomes are nibbled before they fuse, researchers report
4. Chromosome assessment could predict increased risk of death from age-related disease
5. Chromosome centers defined and sequenced for model plant
6. Discovery: Chromosomes Found To End In Big Loops
7. UI Researchers Find Possible Genetic Link Between The X Chromosome And Ovarian Cancer
8. Counting X Chromosomes To Determine Sex
9. Genetic Code Of Chromosome Of Malaria Parasite Deciphered
10. Hopkins And International Team Maps First Major Cancer Gene To X Chromosome
11. UNC Scientists Succeed In Inserting Gene In Human Cells Via Artificial Chromosome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... , ... August 25, 2020 ... ... biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, ... in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution ...
(Date:8/21/2020)... ... 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application ... COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based in Basel, ... license agreements with Housey Pharma’s HMI subsidiary to gain access to its core-enabling ... Research and Development spending in excess of US $10 billion. , Scientists at ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone Partners , ... announced the placement of Julianne Averill , CPA, as Chief Financial Officer ... operations and implementing key business strategies to accelerate Alveo’s growth as the company ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading ... Scientific Advisory Board (SAB) to research the medical potential of terpenes and the potential ... combined with terpenes. The board is focused on expanding the recently launched line of ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 12, 2020 , ... ... Group, Inc. (EMMA International), a global leader in FDA compliance consulting has ... the nation’s fastest-growing private companies. The list represents a unique look at the ...
Breaking Biology Technology:
Cached News: